| SC 13G/A | 2023-06-13 | BML Investment Partners, L.P. | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-06-12 | RA CAPITAL MANAGEMENT, L.P. | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2023-06-08 | Shin Nippon Biomedical Laboratories, Ltd. | Satsuma Pharmaceuticals, Inc. | 1,000 | 100.0% | EDGAR |
| SC 13D/A | 2023-05-02 | Growth Equity Opportunities 17, LLC | Satsuma Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13D/A | 2023-04-18 | RA CAPITAL MANAGEMENT, L.P. | Satsuma Pharmaceuticals, Inc. | 5,944,252 | 17.9% | EDGAR |
| SC 13D/A | 2023-04-17 | Shin Nippon Biomedical Laboratories, Ltd. | Satsuma Pharmaceuticals, Inc. | 2,794,113 | 8.4% | EDGAR |
| SC 13G/A | 2023-02-14 | SAMLYN CAPITAL, LLC | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-10 | TPG GP A, LLC | Satsuma Pharmaceuticals, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2023-02-08 | BML Investment Partners, L.P. | Satsuma Pharmaceuticals, Inc. | 6,440,000 | 19.4% | EDGAR |
| SC 13D/A | 2023-01-27 | Growth Equity Opportunities 17, LLC | Satsuma Pharmaceuticals, Inc. | 2,488,587 | 7.5% | EDGAR |
| SC 13G/A | 2022-11-16 | COMMODORE CAPITAL LP | Satsuma Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2022-11-16 | BML Investment Partners, L.P. | Satsuma Pharmaceuticals, Inc. | 6,440,000 | 19.4% | EDGAR |
| SC 13G/A | 2022-02-25 | SAMLYN CAPITAL, LLC | Satsuma Pharmaceuticals, Inc. | 2,570,292 | 8.2% | EDGAR |
| SC 13G/A | 2022-02-14 | COMMODORE CAPITAL LP | Satsuma Pharmaceuticals, Inc. | 3,711,286 | 11.8% | EDGAR |
| SC 13G | 2022-02-14 | SAMLYN CAPITAL, LLC | Satsuma Pharmaceuticals, Inc. | 1,769,854 | 5.6% | EDGAR |
| SC 13G/A | 2022-02-11 | TPG GP A, LLC | Satsuma Pharmaceuticals, Inc. | 1,885,939 | 6.0% | EDGAR |
| SC 13G/A | 2021-10-19 | COMMODORE CAPITAL LP | Satsuma Pharmaceuticals, Inc. | 3,208,761 | 10.2% | EDGAR |
| SC 13G/A | 2021-04-09 | MORGAN STANLEY | Satsuma Pharmaceuticals, Inc. | 577,022 | 1.8% | EDGAR |
| SC 13D | 2021-03-31 | Shin Nippon Biomedical Laboratories, Ltd. | Satsuma Pharmaceuticals, Inc. | 2,794,113 | 8.9% | EDGAR |
| SC 13D | 2021-03-15 | Growth Equity Opportunities 17, LLC | Satsuma Pharmaceuticals, Inc. | 2,992,958 | 9.5% | EDGAR |